Equities

Adverum Biotechnologies Inc

Adverum Biotechnologies Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.75
  • Today's Change-0.42 / -6.81%
  • Shares traded873.75k
  • 1 Year change-33.14%
  • Beta0.9132
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform5
Hold1
Sell0
Strong Sell0

Share price forecast in USD

The 7 analysts offering 12 month price targets for Adverum Biotechnologies Inc have a median target of 32.00, with a high estimate of 40.00 and a low estimate of 10.00. The median estimate represents a 456.52% increase from the last price of 5.75.
High595.7%40.00
Med456.5%32.00
Low73.9%10.00

Earnings history & estimates in USD

On Nov 04, 2024, Adverum Biotechnologies Inc reported 3rd quarter 2024 losses of -1.30 per share. This result was in line with the consensus of the 7 analysts following the company and exceeded last year's 3rd quarter results by 60.61%.
The next earnings announcement is expected on Mar 17, 2025.
Average growth rate+14.92%
Adverum Biotechnologies Inc reported annual 2023 losses of -11.60 per share on Mar 18, 2024.
Average growth rate-5.91%
More ▼

Revenue history & estimates in USD

Adverum Biotechnologies, Inc. had 3rd quarter 2024 revenues of 1.00m. This bettered the 100.00k consensus of the 5 analysts covering the company. This was 72.22% below the prior year's 3rd quarter results.
Average growth rate0.00%
Adverum Biotechnologies, Inc. had revenues for the full year 2023 of 3.60m.
Average growth rate-100.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.